|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910463246803321 |
|
|
Autore |
Jung Sin-Ho |
|
|
Titolo |
Randomized phase II cancer clinical trials / / Sin-Ho Jung |
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Boca Raton, Fla. : , : Taylor & Francis Group, , 2013 |
|
|
|
|
|
|
|
ISBN |
|
0-429-06447-0 |
1-4398-7186-8 |
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (236 p.) |
|
|
|
|
|
|
Collana |
|
Chapman & Hall/CRC biostatistics series |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Cancer - Research |
Clinical trials |
Electronic books. |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references. |
|
|
|
|
|
|
Nota di contenuto |
|
Front Cover; Contents; Preface; Chapter 1 Introduction; Chapter 2 Single-Arm Phase II Trial Designs; Chapter 3 Inference on the Binomial Probability in Single-Arm Multistage Clinical Trials; Chapter 4 Single-Arm Phase II Clinical Trials with Time-to-Event Endpoints; Chapter 5 Single-Arm Phase II Trials with Heterogeneous Patient Populations: Binary and Survival Outcomes; Chapter 6 Randomized Phase II Trials for Selection: No Prospective Control Arms; Chapter 7 Randomized Phase II Cancer Clinical Trials with a Prospective Control on Binary Endpoints (I): Two-Sample Binomial Test |
Chapter 8 Randomized Phase II Cancer Clinical Trials with a Prospective Control on Binary Endpoints (II): Fisher's Exact TestChapter 9 Randomized Phase II Trials with Heterogeneous Patient Populations: Stratified Fisher's Exact Test; Chapter 10 Randomized Phase II Clinical Trials Based on Survival Endpoints: Two-Sample Log-Rank Test; Chapter 11 Some Flexible Phase II Clinical Trial Designs; Back Cover |
|
|
|
|
|
|
|
|
Sommario/riassunto |
|
In cancer research, a traditional phase II trial is designed as a single-arm trial that compares the experimental therapy to a historical control. This simple trial design has led to several adverse issues, including increased false positivity of phase II trial results and negative phase III trials. To rectify these problems, oncologists and biostatisticians have begun to use a randomized phase II trial that compares an |
|
|
|
|